Catalyst Pharmaceutical (CPRX Quick QuoteCPRX - Free Report) reported $146.56 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 19.4%. EPS of $0.68 for the same period compares to $0.56 a year ago.

The reported revenue represents a surprise of +5.3% over the Zacks Consensus Estimate of $139.19 million. With the consensus EPS estimate being $0.58, the EPS surprise was +17.24%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product revenue,net- FIRDAPSE: $84.85 million versus the four-analyst average estimate of $88.01 million.
• Revenues- Product revenue,net- FYCOMPA: $34.33 million versus the four-analyst average estimate of $25.92 million.
• Revenues- Product revenue,net- AGAMREE: $27.36 million versus $25.12 million estimated by four analysts on average.
• Revenues- Product revenue,net: $146.54 million compared to the $139.05 million average estimate based on four analysts. The reported number represents a change of +19.5% year over year.
• Revenues- License and other: $0.02 million versus the three-analyst average estimate of $0.18 million. The reported number represents a year-over-year change of -59.7%.

View all Key Company Metrics for Catalyst here>>>

Shares of Catalyst have returned +7.1% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.